Q4 Results Above Outlook
Net sales of $540M in Q4 2025, up 1% at constant exchange rates (CER) and ahead of outlook (which assumed flat sales). Adjusted diluted EPS was $0.62 at CER vs. outlook of about $0.60.
Qiagen
· QGEN
February 4th, 2026
Summary
- Earnings Call Date:
- 2026-02-04
- Change Since:
- -25.10%
- Next Earnings Date:
- 2026-07-23
Earnings Call Sentiment
PositiveThe call presents a broadly positive operational and financial picture: QIAGEN beat Q4 and full-year outlooks, delivered margin expansion and strong free cash flow, progressed multiple growth pillars (Sample Technologies, QuantiFERON, QIAstat, QIAcuity, QDI), completed strategic acquisitions (Parse, Genoox) and set 2026 guidance for continued profitable growth. Notable near-term challenges include declines in PCR/NGS consumables, regional softness (U.S. and China), tariff and FX headwinds, and short-term dilution from Parse and discontinued product lines that weigh on Q1/first-half 2026. Management expects improvement and acceleration into H2 2026 driven by new product launches and strengthened growth pillars.
Company Guidance
QIAGEN guided 2026 to at least 5% sales growth at constant exchange rates (CER) and adjusted diluted EPS of at least $2.50 at CER, while expecting the adjusted operating income margin to remain about 29.5% (despite ~160 basis points of headwinds from the Parse acquisition, tariffs and FX); currency is expected to be a ~1‑point tailwind to full‑year sales (neutral to EPS) and ~2–3 points tailwind to Q1 sales. For Q1 the company expects net sales growth of at least 1% CER versus Q1‑25 ($483 million) and adjusted EPS of at least $0.54 at CER (vs $0.55 a year ago), noting Q1 headwinds of roughly $10M from the discontinuation of NeuMoDx/Dialunox (~2 percentage points), ~$10M from cautious life‑science spending (~2 points), and a low‑single‑digit QuantiFERON comparison (≈$6–7M, ~1 point); Parse will dilute Q1 EPS by ~$0.02 and U.S. tariffs by ~ $0.02. Management expects H1 growth of roughly 2–3% CER with an H2 acceleration to reach the full‑year target, a normalized run rate near 6% CER after roll‑offs, a currency‑neutral EPS impact, and continued focus on growth pillars (targeting ~9% CER growth in 2026 with Sample Technologies ≈ $720M, QuantiFERON ≈ $535M, QIAstat ≈ $160M, QIAcuity ≈ $100M and QDI ≈ $125M); the company completed a $500M share repurchase in January and shows pro‑forma leverage of ~1.3x net debt/adjusted EBITDA.
Full-Year 2025 Performance
Full-year net sales of $2.09B, up 5% CER (at the high end of the 4%–5% outlook). Adjusted diluted EPS was $2.40 at CER (reported $2.38), above guidance and achieved after two upward revisions during the year.
Growth Pillars Momentum
Combined sales from Sample Technologies, QuantiFERON, QIAstat, QIAcuity and QIAGEN Digital Insights reached $1.49B in 2025, up 8% CER year-over-year; management remains on track for at least $2B from these pillars by 2028.
Sample Technologies Strength & Strategic Expansion
Sample Technologies grew mid-single-digits in Q4 (+5% CER) and 2% CER for full year; installed base ~31,400 placements; liquid biopsy sample prep grew >30%; completed Parse Biosciences acquisition (adds single-cell capability).
QuantiFERON Growth and Product Innovation
QuantiFERON grew 5% CER in Q4 and 10% CER for the full year 2025; next-gen TB assay increases throughput up to ~75% and reduces turnaround time ~25%; U.S. launch planned in 2026 to capture underpenetrated latent TB market.
QIAstat Strong Adoption
QIAstat grew 15% CER in Q4 and 24% CER for full year 2025 with cumulative installed base >5,200 instruments; menu expansion (including blood culture panels) supports consumable-led growth and a $160M sales target for 2026.
QIAcuity Consumables and Installed Base Growth
Digital PCR consumables delivered double-digit growth in 2025 and cumulative QIAcuity placements exceeded 3,200 systems; over 100 instruments placed per quarter in Q4 despite a cautious capital spending environment.
Bioinformatics (QDI) Progress
QIAGEN Digital Insights delivered continued growth supported by the Genoox integration and AI-enabled workflows; company plans ~14 AI-enabled software solutions over next 2 years and targets ~$125M for QDI in 2026.
Margin Expansion and Profitability
Adjusted operating income margin expanded 80 basis points to 29.5% in 2025. Excluding tariffs and adverse FX headwinds (~120 bps), margin improvement was roughly 200 bps, supporting confidence toward the 31%+ midterm target.
Strong Cash Generation and Capital Returns
Operating cash flow of $654M and free cash flow of $453M in 2025; returned over $1.1B to shareholders since 2024, completed $500M synthetic share repurchase in Jan 2026; pro forma net leverage ~1.3x net debt / adjusted EBITDA.
2026 Financial Outlook
Full-year 2026 guidance: at least 5% CER sales growth and adjusted EPS of at least $2.50 at CER. First-quarter 2026 guidance: at least 1% CER sales growth and EPS of at least $0.54 at CER; management expects growth acceleration in H2 2026.
Operator
Ladies and gentlemen, thank you for standing by. I am Katie, your call operator. Welcome, and thank you for joining QIAGEN's Fourth Quarter 2025 Earnings Conference Call Webcast. [Operator Instructions] Please be advised this call is being recorded at QIAGEN's request and will be made available on their Internet site. [Operator Instructions] At this time, I'd like to introduce your host, Daniel Wendorff, Vice President and Head of Relations at QIAGEN. Please go ahead.
Daniel Wendorff
Thank you, operator, and welcome to our call for the fourth quarter of 2025. We appreciate your time and interest in QIAGEN. Joining the call today are Thierry Bernard, our Chief Executive Officer; and Roland Sackers, our Chief Financial Officer. Also joining us is Dr. Domenica Martorana from our Investor Relations team. As always, today's call is being webcast live and will be archived in the IR section of our website at www.qiagen.com, where you can find the press release and presentation accompanying this call. Please also note that this call will include forward-looking statements. Actual results may differ materially from those projected due to a number of factors outlined in our most recent Form 20-F and other filings with the U.S.
Securities and Exchange Commission. We will also refer to certain financial measures not prepared in accordance with U.S. generally accepted accounting principles or GAAP, that provide additional insights into our performance. Reconciliations to the most directly comparable GAAP figures are in the release and presentation. All references to earnings per share refer to adjusted...
Subscribe to unlock transcripts
Get The Fly Pro 7 days for free